Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Viridian Therapeutics, Inc. at current levels.
A $1.7B biotech sitting on top-line TED data and a subcutaneous follow-on aimed at Tepezza's $2B franchise, mispriced after a brutal year.
Where VRDN is headed
Viridian is a binary story dressed up as a platform. The whole company hinges on whether veligrotrug, their IV anti-IGF-1R antibody, can land a clean approval in thyroid eye disease and credibly chip away at Amgen's Tepezza, a franchise that did roughly $1.9B in 2025 and has spent the last two years bleeding share to safety concerns (hearing loss, hyperglycemia). The Phase 3 THRIVE and THRIVE-2 readouts already showed proptosis responder rates broadly competitive with Tepezza on a shorter five-infusion course. The interesting product, though, is elegrobart (VRDN-003), the subcutaneous, half-life-extended version. If that hits in the pivotal program reading out across 2026 into 2027, Viridian goes from being a hospital-infusion me-too to the only at-home option in TED.
Read the full Compass Direction on VRDN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $17.24).
See the full VRDN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Viridian Therapeutics, Inc. at current levels. A $1.7B biotech sitting on top-line TED data and a subcutaneous follow-on aimed at Tepezza's $2B franchise, mispriced after a brutal year.
What is VRDN's Compass Score?
Viridian Therapeutics, Inc. scores 81/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for VRDN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the VRDN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.